The EMPA-Kidney trial will stop early due to evidence of Jardiance’s positive efficacy among patients with chronic kidney disease, according to a press release.
As the largest current SGLT2 inhibitor trial in CKD, EMPA-Kidney examined kidney disease progression and cardiovascular death in more than 6,000 adults with CKD when treated with Jardiance (empagliflozin). The early end of the trial comes from a recommendation by the trial’s independent data monitoring committee based on a formal interim assessment measuring positive efficacy.
«We are thrilled that the trial has shown that
Jardiance phase 3 trial shows efficacy in patients with CKD, trial will stop early
The EMPA-Kidney trial will stop early due to evidence of Jardiance’s positive efficacy among patients with chronic kidney disease, according to a press release.
As the largest current SGLT2 inhibitor trial in CKD, EMPA-Kidney examined kidney disease progression and cardiovascular death in more than 6,000 adults with CKD when treated with Jardiance (empagliflozin). The early end of the trial comes from a recommendation by the trial’s independent data monitoring committee based on a formal interim assessment measuring positive efficacy.
"We are thrilled that the trial has shown that